CJC-1295 Buyer's Guide: 4 Decisions Before You Buy

Your pituitary gland does not release growth hormone in a steady stream. It fires in sharp bursts, several times a day, with the largest pulse happening about an hour after you fall asleep, and then it goes quiet between those pulses, and that pattern of signal and silence is exactly what makes the whole system work.

Understanding why that matters is the entire reason CJC-1295 without DAC is the only version worth buying.

Here is the full chain before we get into the details. Your hypothalamus releases something called growth hormone releasing hormone, or GHRH, which is a signaling peptide that travels to your pituitary and tells it to release growth hormone. The pituitary responds to that signal with a pulse of growth hormone, which then travels through the blood and acts on the liver to produce something called IGF-1, which is insulin-like growth factor 1, and IGF-1 is what drives most of the downstream effects people are actually chasing: body composition changes, recovery, cellular repair. CJC-1295 is a synthetic analog of GHRH, meaning it mimics that hypothalamic signal. That is where it sits in the chain. It is not growth hormone. It is the upstream trigger.

Now here is where the DAC question enters.

DAC stands for drug affinity complex, which is a chemical modification attached to the CJC-1295 molecule that causes it to bind to albumin, a protein that circulates in your blood. That binding protects the peptide from being broken down, and the result is a half-life of roughly seven days instead of the natural thirty-minute window that unmodified GHRH operates in. That sounds like a convenience upgrade because you only need to inject once or twice a week instead of daily.

But it eliminates the thing you were trying to preserve.

The pituitary is not designed to receive a constant low-level GHRH signal. It is designed to receive a sharp pulse, respond with a burst of growth hormone, and then return to baseline while somatostatin, which is the body's natural growth hormone brake, quiets everything back down. That cycle of stimulation and suppression is what maintains receptor sensitivity and keeps the feedback loop functional. When you run CJC-1295 with DAC, you are replacing that pattern with a flat, sustained baseline of GHRH signal, and instead of sharp pulses of growth hormone, you get a blunted, chronic elevation that looks nothing like endogenous physiology.

If what you want is flat, chronically elevated growth hormone, exogenous recombinant growth hormone does that with decades of clinical data behind it. The entire clinical rationale for using a secretagogue instead of growth hormone is that you preserve the pulsatile feedback loop and keep your own axis running. DAC defeats that rationale entirely.

So no DAC is the starting point, and from there the next question is how you are actually running the compound.

Most people pair CJC-1295 without DAC with Ipamorelin, and you can buy them as a premixed blend or in separate vials. If you are using a blend, the math matters. Five milligrams of CJC plus five milligrams of Ipamorelin in two milliliters of bacteriostatic water gives you 2500 micrograms of each per milliliter, which works out to 250 micrograms of each compound per 10 units on an insulin syringe. Get that ratio wrong and you are dosing inaccurately without knowing it.

Ipamorelin works through a completely different receptor than CJC-1295 does, and that difference is what drives the cycling question.

Ipamorelin acts on something called the GHSR1a receptor, which is the ghrelin receptor, and it uses a pathway involving something called beta-arrestin to trigger growth hormone release from the pituitary. What the research shows is that GHSR1a receptors undergo desensitization with sustained stimulation, meaning the cell surface literally reduces the number of available receptors in response to chronic activation, so the same dose of Ipamorelin produces progressively less response over time. In practice, IGF-1 levels can drop 20 to 30 percent from peak after 12 to 16 weeks of continuous use even without changing the dose.

That is why you cycle three months on, one month off. Not because of the CJC side. Because of the Ipamorelin side.

The GHRH receptors that CJC-1295 acts on do not appear to have this problem. Tesamorelin, which is a stabilized GHRH analog and the only FDA-approved compound in this class, was run continuously for 52 weeks in the clinical trials that supported its approval, and IGF-1 levels that were established by week 26 held steady all the way through week 52 with no sign of receptor dropout or diminishing response. If GHRH receptor desensitization were a meaningful clinical issue, that 52-week run would have caught it. It did not.

So the cycling protocol is entirely driven by ghrelin receptor biology, and if you ever run CJC without a ghrelin receptor agonist, the cycling rationale changes completely.

The last decision is when secretagogues stop being the right tool.

Secretagogues work within your biological ceiling. They amplify what your pituitary can produce on its own, they keep the feedback loop intact, and they preserve the axis that lets you still respond to your own hypothalamic signaling. That is a real advantage over exogenous growth hormone for most people in most situations. But that ceiling is real, and if your goals require more growth hormone than your pituitary can produce regardless of how well you stimulate it, secretagogues cannot close that gap.

There is also a direct biochemical incompatibility. After a single injection of exogenous growth hormone, the resulting spike triggers somatostatin release, and that somatostatin inhibits the GHRH pathway by 86 percent. That means the CJC-1295 you are paying for cannot do its job while exogenous growth hormone is active in your system. Running them together is not synergistic. It is pharmacologically self-defeating.

The decision, then, is not "which is better" in the abstract. It is whether your actual goals are achievable within your own biological output. If they are, secretagogues preserve something worth preserving. If they are not, you stop trying to optimize a ceiling you have already outgrown, and you switch.

The pulsatile pattern is not a quirk of human physiology. It is the mechanism. Everything about how you choose and use these compounds follows from that single fact.

---

References

1. FDA Prescribing Information. EGRIFTA (tesamorelin). 2025 — 52-week continuous dosing, IGF-1 levels maintained at week-26 levels through week 52
2. Bowers CY et al. On the in vitro and in vivo activity of a new synthetic hexapeptide. Endocrinology. 1984 — GHRP/ghrelin receptor agonist mechanism
3. PNAS. Discovery of a functionally selective ghrelin receptor (GHSR1a) ligand. 2022 — β-arrestin mediated GHSR1a desensitization mechanism
4. Veldhuis JD et al. Somatostatin inhibition of GHRH-stimulated GH secretion. J Clin Endocrinol Metab — 86% GHRH pathway inhibition after exogenous GH
5. Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. NEJM. 2007 — Tesamorelin 26-week clinical trial efficacy

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness